ArticleHeart rhythm O22026
Reduction in new-onset device-detected atrial fibrillation: A prospective 2-center study comparing left bundle branch pacing with conventional right ventricular pacing.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Right ventricular pacing (RVP) has been associated with an increased risk of atrial fibrillation (AF). Objective: We aim to compare the incidence of new-onset AF between left bundle branch pacing (LBBP) and RVP. Methods: We conducted a prospective, observational, 2-center study recruiting patients with pacemaker implantation who were at high risk of developing AF (ie, patients older than 70 years). The primary end point was time to the first occurrence of device-detected AF with clinical significance (ie, AF lasting >6 minutes), whereas the secondary end point was time to the first episode of AF that could require oral anticoagulation (ie, AF lasting >24 hours). Multivariate Cox regression models were used to evaluate the effect of LBBP on AF occurrence. Results: The final evaluation included 412 patients (212 (51.4%) in the LBBP group and 200 (48.5%) in the RVP group). LBBP showed a lower incidence of AF lasting >6 minutes than did RVP (27.4% vs 42%; Conclusion: LBBP reduced the risk of new-onset device-detected AF lasting >6 minutes and decreased the likelihood of new-onset AF episodes lasting >24 hours, compared with RVP in a high-risk population for AF development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.